Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 4/20 | 0.60 |
| ▸ | ATP4B | P51164 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | APP | P05067 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | GLA | P06280 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10571329 | 0.93 | ATP4A (0.64) | ATP4AATP4BRAB9AKDM4ENPC1 | |
| SCHEMBL10574645 | 0.80 | ATP4A (0.63) | ATP4AATP4BRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL10662353 | 0.78 | ATP4A (0.61) | ATP4AATP4BRAB9AMAPTKMT2A | |
| SCHEMBL7686738 | 0.75 | ATP4A (1.00) | ATP4AATP4BRAB9AKDM4ENPC1 | |
| SCHEMBL15462904 | 0.75 | ATP4A (0.83) | ATP4AATP4BRAB9AKDM4ENPC1 | |
| SCHEMBL13198328 | 0.74 | KDM4E (0.70) | ATP4AATP4BRAB9AKDM4ENPC1 | |
| SCHEMBL7682417 | 0.74 | ATP4A (0.67) | ATP4AATP4BRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL10659751 | 0.73 | ATP4A (0.66) | ATP4AATP4BRAB9AMAPTGAA | |
| SCHEMBL10661906 | 0.73 | ATP4A (0.67) | ATP4AATP4BMAPTALDH1A1 | |
| SCHEMBL10571336 | 0.73 | ATP4A (1.00) | ATP4AATP4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436939-B2 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS INCLUDING SLEEP/WAKE DISORDERS, DEMENTIA, ALZHEIMER'S DISEASE, EPILEPSY, NARCOLEPSY, EATING DISORDERS, MOTION SICKNESS, VERTIGO | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-08-20 | — | — | US | claimed |
| US-20010044439-A1 | Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as H3 antagonists | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2001-11-22 | — | — | US | claimed |
| WO-2001074810-A2 | METHOD FOR USING 2-ARYLOXYALKYLAMINOBENZOXAZOLES AND 2-ARYLOXYALKYLAMINOBENZOTHIAZOLES AS H3 ANTAGONISTS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | claimed |
| US-6436939-B2 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS INCLUDING SLEEP/WAKE DISORDERS, DEMENTIA, ALZHEIMER'S DISEASE, EPILEPSY, NARCOLEPSY, EATING DISORDERS, MOTION SICKNESS, VERTIGO | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-08-20 | — | — | US | disclosed |
| US-20010044439-A1 | Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as H3 antagonists | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2001-11-22 | — | — | US | disclosed |
| WO-2001074810-A2 | METHOD FOR USING 2-ARYLOXYALKYLAMINOBENZOXAZOLES AND 2-ARYLOXYALKYLAMINOBENZOTHIAZOLES AS H3 ANTAGONISTS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
| US-4861897-A | 2-Aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044439-A1 | Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as H3 antagonists | HRH3, HRH4, HRH2 | ATP4A 2706/4885ATP4B 2670/4885RAB9A 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.